Immunome closed at $19.52 on Nov 4, down 3.89%, 34.6% below its 52-week closing high. Volume of 3.5M shares was 2.41× its 20-day average (well above normal).
Split-adjusted performance: +1.1% over one month, -16.1% over six months, +14.8% over one year.
Short interest was 17.3M shares at the Oct 15 settlement, up 3.1% from the prior report (17.1% of float, 12.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMNMImmunome | $19.52 | −3.89% | −16.1% | −100.0% | — | — | $2.30B | |
| VERAVera Therapeutics | $31.97 | +4.10% | −12.6% | — | — | — | $2.30B | Compare |
| BHVNBiohaven | $15.24 | −2.37% | +51.8% | — | — | — | $2.30B | Compare |
| AUPHAurinia Pharmaceuticals | $17.11 | +3.32% | +5.3% | +13.9% | 37.9% | 7.3 | $2.29B | Compare |
| PVLAPalvella Therapeutics | $162.28 | +6.11% | +24.7% | — | — | — | $2.34B | Compare |
| SEPNSepterna | $47.88 | +9.57% | +93.8% | +22375.6% | −48.7% | — | $2.23B | Compare |
| TRLVTrulieve Cannabis | $11.60 | +0.52% | — | — | −149.8% | — | $2.23B | Compare |
| ZYMEZymeworks | $30.94 | +2.69% | +12.1% | −90.6% | −980.8% | — | $2.22B | Compare |
| PRGOPERRIGO | $15.83 | +0.83% | +29.1% | −3.2% | 7.3% | — | $2.20B | Compare |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
